Agomab Reports 2025 Financial Results and Future Milestones
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy AGMB?
Source: NASDAQ.COM
- Expanded Financial Loss: Agomab Therapeutics reported a net loss of €62.55 million for the fiscal year 2025, up from €46.27 million the previous year, indicating increased R&D expenditures that may pressure short-term stock performance.
- Strong Cash Reserves: As of December 31, 2025, the company held €116.5 million in cash and cash investments, with gross proceeds of $208 million from its IPO expected to extend its cash runway into the first half of 2029, ensuring operational stability for the coming years.
- Clinical Trial Advancements: Agomab is set to initiate a Phase 2b study for Fibrostenosing Crohn's Disease and a Phase 2 study for Idiopathic Pulmonary Fibrosis in the second half of 2026, demonstrating the company's commitment to advancing its key investigational candidates.
- Stock Price Fluctuations: Since February 2026, AGMB shares have traded between $9 and $17.45, closing at $10.70, reflecting a cautiously optimistic market sentiment regarding the company's upcoming clinical results.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGMB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGMB
Wall Street analysts forecast AGMB stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 10.550
Low
Averages
High
Current: 10.550
Low
Averages
High
About AGMB
Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agomab Reports 2025 Financial Results and Future Milestones
- Expanded Financial Loss: Agomab Therapeutics reported a net loss of €62.55 million for the fiscal year 2025, up from €46.27 million the previous year, indicating increased R&D expenditures that may pressure short-term stock performance.
- Strong Cash Reserves: As of December 31, 2025, the company held €116.5 million in cash and cash investments, with gross proceeds of $208 million from its IPO expected to extend its cash runway into the first half of 2029, ensuring operational stability for the coming years.
- Clinical Trial Advancements: Agomab is set to initiate a Phase 2b study for Fibrostenosing Crohn's Disease and a Phase 2 study for Idiopathic Pulmonary Fibrosis in the second half of 2026, demonstrating the company's commitment to advancing its key investigational candidates.
- Stock Price Fluctuations: Since February 2026, AGMB shares have traded between $9 and $17.45, closing at $10.70, reflecting a cautiously optimistic market sentiment regarding the company's upcoming clinical results.
See More
Agomab's IPO Boosts Cash Runway into 2029
- Successful IPO Financing: Agomab completed its IPO in February 2026, raising approximately $208 million in gross proceeds, which is expected to extend the company's cash reserves into the first half of 2029, ensuring funding for its R&D and operational needs.
- Clinical Trial Progress: The company is having positive interactions with the FDA to finalize the design of the Phase 2b study for FSCD, which is expected to initiate in the second half of 2026, marking a significant advancement in its efforts to treat fibro-inflammatory diseases.
- Increased R&D Spending: Research and development expenses for 2025 totaled €48.9 million, up 24.5% from €39.3 million in 2024, primarily due to rising clinical trial costs, reflecting the company's commitment to accelerating product development in key programs.
- Improved Financial Performance: Although the net loss for 2025 was €62.5 million, an increase from €46.3 million in 2024, this indicates ongoing investments in business expansion and clinical trials, with future revenue growth anticipated from new drug launches.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these firms.
- Market Dynamics Overview: While specific company names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the related stocks.
- Investor Considerations: For those considering buying AMLX stock, analysts' opinions will serve as a crucial reference point, potentially impacting their investment strategies and market confidence.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, although specific rating details are not disclosed.
See More
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
See More
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts
- SpyGlass Pharma's Strong Performance: SpyGlass Pharma (SGP) opened at $24.00 on its Nasdaq debut, reflecting a 50% increase from its IPO price of $16.00, and surged to $26.00 during trading, indicating a 63% rise, showcasing strong market interest in its ocular treatment candidates.
- Agomab Therapeutics Decline: In contrast, Agomab Therapeutics (AGMB) opened at $14.70, representing an ~8% drop from its IPO price, and fell further to $14.00, marking a 13% decline, indicating cautious market sentiment towards its immunology and inflammatory disease treatments.
- Significant Fundraising: The two companies priced their offerings late Thursday to raise a combined total of $350 million in gross proceeds, reflecting ongoing investor interest and enthusiasm in the biotech sector.
- Market Volatility Impact: SpyGlass's stock was halted for volatility but quickly rebounded, indicating investor confidence in its growth potential, while Agomab's continued decline may affect its future fundraising and market performance.
See More
SpyGlass Pharma and Agomab IPO Pricing Announced
- SpyGlass Pharma IPO: SpyGlass Pharma (SGP) is set to begin trading on Nasdaq after pricing its IPO at $16.00 per share for 9.375 million shares, aiming to raise approximately $150 million to fund phase 3 trials for its Bimatoprost Drug Pad-IOL System, with data expected in 2027, highlighting its potential in glaucoma treatment.
- Agomab Therapeutics Offering: Belgian biotech Agomab Therapeutics (AGMB) also priced its offering at $16.00 per share for 12.5 million American Depositary Shares, targeting $200 million in gross proceeds to support a Phase 2b trial for its drug ontunisertib, aimed at treating fibrostenosing Crohn’s disease, set to begin in H2 2026.
- Positive Market Response: The combined expected proceeds of $350 million from both companies reflect strong investor interest in the biotech sector, particularly in innovative drug development for ophthalmology and gastrointestinal diseases.
- Clinical Trial Prospects: The clinical-stage candidates from SpyGlass and Agomab present significant market opportunities, as successful trials could enhance their competitiveness in the biopharmaceutical industry and attract further investment.
See More
Agomab Reports 2025 Financial Results and Future Milestones
- Expanded Financial Loss: Agomab Therapeutics reported a net loss of €62.55 million for the fiscal year 2025, up from €46.27 million the previous year, indicating increased R&D expenditures that may pressure short-term stock performance.
- Strong Cash Reserves: As of December 31, 2025, the company held €116.5 million in cash and cash investments, with gross proceeds of $208 million from its IPO expected to extend its cash runway into the first half of 2029, ensuring operational stability for the coming years.
- Clinical Trial Advancements: Agomab is set to initiate a Phase 2b study for Fibrostenosing Crohn's Disease and a Phase 2 study for Idiopathic Pulmonary Fibrosis in the second half of 2026, demonstrating the company's commitment to advancing its key investigational candidates.
- Stock Price Fluctuations: Since February 2026, AGMB shares have traded between $9 and $17.45, closing at $10.70, reflecting a cautiously optimistic market sentiment regarding the company's upcoming clinical results.
See More
Agomab's IPO Boosts Cash Runway into 2029
- Successful IPO Financing: Agomab completed its IPO in February 2026, raising approximately $208 million in gross proceeds, which is expected to extend the company's cash reserves into the first half of 2029, ensuring funding for its R&D and operational needs.
- Clinical Trial Progress: The company is having positive interactions with the FDA to finalize the design of the Phase 2b study for FSCD, which is expected to initiate in the second half of 2026, marking a significant advancement in its efforts to treat fibro-inflammatory diseases.
- Increased R&D Spending: Research and development expenses for 2025 totaled €48.9 million, up 24.5% from €39.3 million in 2024, primarily due to rising clinical trial costs, reflecting the company's commitment to accelerating product development in key programs.
- Improved Financial Performance: Although the net loss for 2025 was €62.5 million, an increase from €46.3 million in 2024, this indicates ongoing investments in business expansion and clinical trials, with future revenue growth anticipated from new drug launches.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these firms.
- Market Dynamics Overview: While specific company names are not mentioned, changes in analyst ratings typically influence investor decisions, potentially leading to price fluctuations in the related stocks.
- Investor Considerations: For those considering buying AMLX stock, analysts' opinions will serve as a crucial reference point, potentially impacting their investment strategies and market confidence.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, although specific rating details are not disclosed.
See More
Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes
Jennifer Garner's Characters: Garner is known for her roles as Sidney Bristow in Alias and Elektra in Marvel films, where she faced tough adversaries.
Current Challenge: The actress is now dealing with the challenges posed by unpredictable investors in her entrepreneurial ventures.
Entrepreneurial Success: Despite the challenges, Garner appears to be successfully navigating the investment landscape.
Transition from Acting to Business: Garner's shift from acting to entrepreneurship highlights her versatility and determination in facing new challenges.
See More
SpyGlass Pharma and Agomab's Contrasting Nasdaq Debuts
- SpyGlass Pharma's Strong Performance: SpyGlass Pharma (SGP) opened at $24.00 on its Nasdaq debut, reflecting a 50% increase from its IPO price of $16.00, and surged to $26.00 during trading, indicating a 63% rise, showcasing strong market interest in its ocular treatment candidates.
- Agomab Therapeutics Decline: In contrast, Agomab Therapeutics (AGMB) opened at $14.70, representing an ~8% drop from its IPO price, and fell further to $14.00, marking a 13% decline, indicating cautious market sentiment towards its immunology and inflammatory disease treatments.
- Significant Fundraising: The two companies priced their offerings late Thursday to raise a combined total of $350 million in gross proceeds, reflecting ongoing investor interest and enthusiasm in the biotech sector.
- Market Volatility Impact: SpyGlass's stock was halted for volatility but quickly rebounded, indicating investor confidence in its growth potential, while Agomab's continued decline may affect its future fundraising and market performance.
See More
SpyGlass Pharma and Agomab IPO Pricing Announced
- SpyGlass Pharma IPO: SpyGlass Pharma (SGP) is set to begin trading on Nasdaq after pricing its IPO at $16.00 per share for 9.375 million shares, aiming to raise approximately $150 million to fund phase 3 trials for its Bimatoprost Drug Pad-IOL System, with data expected in 2027, highlighting its potential in glaucoma treatment.
- Agomab Therapeutics Offering: Belgian biotech Agomab Therapeutics (AGMB) also priced its offering at $16.00 per share for 12.5 million American Depositary Shares, targeting $200 million in gross proceeds to support a Phase 2b trial for its drug ontunisertib, aimed at treating fibrostenosing Crohn’s disease, set to begin in H2 2026.
- Positive Market Response: The combined expected proceeds of $350 million from both companies reflect strong investor interest in the biotech sector, particularly in innovative drug development for ophthalmology and gastrointestinal diseases.
- Clinical Trial Prospects: The clinical-stage candidates from SpyGlass and Agomab present significant market opportunities, as successful trials could enhance their competitiveness in the biopharmaceutical industry and attract further investment.
See More
